A provider's guide to helping patients afford Arformoterol. Covers savings programs, coupons, generics, therapeutic alternatives, and cost conversations.
Medication adherence is one of the most significant challenges in COPD management — and cost is one of the biggest reasons patients fall off their treatment plans. For a medication like Arformoterol (Brovana), where the brand-name cash price can exceed $1,000 for a 30-day supply, the financial burden is real and immediate.
As a prescriber, you're often the first person who can intervene. When you understand the cost landscape and can point patients toward the right resources, you don't just save them money — you improve adherence, reduce exacerbations, and keep them out of the emergency department.
This guide covers what your patients are actually paying for Arformoterol, the savings programs available, when to consider therapeutic alternatives, and how to build cost conversations into your clinical workflow.
Understanding the cost landscape helps you anticipate which patients will struggle and intervene proactively.
Most commercial insurance plans cover Arformoterol, though the patient's out-of-pocket cost depends on their formulary tier and plan design:
A 2024 study in the Journal of Managed Care & Specialty Pharmacy found that COPD patients with high out-of-pocket costs were 40% more likely to abandon their prescriptions at the pharmacy counter. For nebulized LABAs specifically, cost-related non-adherence is a documented driver of preventable exacerbations and hospitalizations.
As of 2026, there is no active manufacturer copay card or savings program identified specifically for Brovana or generic Arformoterol from Sunovion Pharmaceuticals.
However, Sunovion does offer a patient assistance program (PAP) for eligible patients:
For your patients who are uninsured or facing significant financial hardship, a PAP application is worth pursuing. Your office staff can often help with the paperwork — it typically requires proof of income, insurance status, and a prescriber signature.
For patients who don't qualify for patient assistance but still face high out-of-pocket costs, discount card programs can provide substantial savings on generic Arformoterol.
A practical tip: keep a printed or digital reference card in your prescribing workflow that lists the top 3-4 discount platforms. When you prescribe Arformoterol, hand it to the patient or have your staff share it during checkout.
When cost is the primary barrier, it's worth evaluating whether the patient needs Arformoterol specifically or whether a therapeutic alternative could work.
The most straightforward cost reduction: prescribe generic Arformoterol Tartrate instead of brand-name Brovana. The generic is FDA-approved, therapeutically equivalent, and available at a fraction of the brand cost. Unless there's a specific clinical reason for brand-name only, generic should be the default.
The only other nebulized LABA for COPD. Formoterol is the racemic version of which Arformoterol is the (R,R)-enantiomer. In clinical practice, both are effective for COPD maintenance. If a patient can't access or afford Arformoterol, Formoterol nebulization solution is a direct therapeutic alternative. Compare availability and pricing — sometimes one is easier to find or cheaper than the other.
If the patient's COPD severity and device competency allow, switching to an inhaler-based LABA may offer cost and convenience advantages:
Before switching a patient off a nebulized medication, assess their ability to use an inhaler correctly. Many patients are on nebulized therapy specifically because they can't effectively use handheld devices — switching them to an inhaler they can't use properly is counterproductive.
For patients on multiple COPD medications, consolidating to a combination inhaler (LABA + LAMA, or LABA + ICS) may reduce total medication costs and improve adherence through simplified dosing. Examples include Bevespi Aerosphere (Formoterol + Glycopyrrolate) and Symbicort (Formoterol + Budesonide).
Cost conversations shouldn't be an afterthought. Here's how to make them part of routine care.
A simple question — "Are you having any trouble affording your medications?" — can uncover adherence problems before they lead to exacerbations. Many patients won't volunteer this information unless asked directly.
Unless there's a documented clinical reason for brand-name, prescribe generic Arformoterol Tartrate. Make sure your prescription allows generic substitution (avoid "Dispense as Written" / "DAW" unless necessary).
Train your medical assistants, nurses, or patient navigators to:
When insurance requires prior authorization for Arformoterol, document the clinical rationale thoroughly:
A well-documented PA request is more likely to be approved on the first attempt, saving time for your staff and medication gaps for your patient.
Keep these resources accessible for your team:
Cost shouldn't be the reason a COPD patient stops taking a medication that's keeping their airways open. As providers, we have more influence over this than we sometimes realize. Prescribing generics, recommending discount cards, facilitating patient assistance applications, and simply asking about cost barriers can make the difference between a patient who stays on therapy and one who abandons it.
Arformoterol is an effective COPD maintenance medication that has a place in many patients' treatment plans. By understanding the cost landscape and keeping savings resources at your fingertips, you can help your patients access the treatment they need — without the financial stress that drives non-adherence.
For more clinical information on Arformoterol, see our guides on drug interactions, side effects, and shortage updates for providers.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
